Views: 0 Author: Site Editor Publish Time: 2026-01-20 Origin: Site
As we navigate 2026, the pharmaceutical and agrochemical industries are increasingly reliant on fluorine to solve complex biological challenges. Ethyl 3-amino-4,4,4-trifluoro-2-butenoate (CAS 372-29-2) is at the heart of this trend. By combining an amine, an unsaturated ester, and a trifluoromethyl group in one rigid scaffold, this molecule allows for the rapid construction of fluorinated heterocycles that are otherwise difficult to synthesize.
It is a fluorinated enamine ester—a derivative of trifluoroacetoacetic acid. Its structure features a CF3 group adjacent to an amine-substituted double bond. Because of its unique electronic configuration, it can exist as E/Z isomers, though the (Z)-isomer is often stabilized by internal hydrogen bonding between the amino group and the carbonyl oxygen.
In 2026, its applications have expanded beyond basic research into large-scale production:
Used to prepare 4-trifluoromethylated 1,3-oxazin-6-ones and various quinolinone derivatives, which serve as precursors for CNS-targeting drugs and anti-infectives.
A critical intermediate for trifluoromethyl-substituted uracil and thiazole herbicides, which offer superior environmental degradation profiles.
Utilized in the synthesis of fluorinated polymers and monomers that require high thermal resistance and unique dielectric properties.
The primary advantage is synthetic efficiency. Instead of multi-step fluorination using hazardous F2 gas or HF, chemists can use this "pre-fluorinated" building block to:
Integrate the CF3 group during the ring-closure step.
The enamine structure directs cyclization with high precision.
The trifluoromethyl group increases the lipophilicity of the final drug, aiding in cellular absorption.
In the context of medicinal biomechanics, the CF3 group provided by this intermediate acts as a bioisostere for a methyl or isopropyl group. However, because fluorine is the most electronegative element, it withdraws electron density, making the drug molecule more resistant to oxidative metabolism by cytochrome P450 enzymes. This extends the half-life of the drug in the human body, allowing for lower dosages and reduced side effects.
The "Surgical Technique"—the precision manufacturing of CAS 372-29-2—typically involves:
Reacting ethyl trifluoroacetate with ethyl acetate in the presence of sodium ethoxide to form the sodium enolate of ethyl trifluoroacetoacetate.
The enolate is reacted directly (often in a one-pot process) with ammonium acetate or anhydrous ammonia in the presence of an acid catalyst like acetic acid.
The product is purified via vacuum fractionation to ensure the removal of hydrates and acetals, which are common byproducts in fluorinated systems.
As a reactive enamine, the product requires careful "Postoperative" management:
It is air-sensitive and can undergo slow hydrolysis; it must be stored under a dry Nitrogen or Argon blanket.
Due to its low melting point (24-26℃), it may arrive as a semi-solid. Storage at 2-8℃ is recommended to maintain stability and prevent darkening.
Must be kept in amber glass or opaque fluorinated HDPE containers to prevent photo-degradation.
Ethyl 3-amino-4,4,4-trifluoro-2-butenoate is a high-performance building block that defines the current 2026 standard for fluorinated organic synthesis. Its ability to simplify the creation of complex, life-saving molecules makes it a staple in the inventory of every advanced chemical manufacturer.
The 2026 market for fluorinated intermediates is witnessing a "Flight to Quality." While global supply chains have stabilized, the demand for CAS 372-29-2 has seen a 15% year-on-year increase. This is driven by the rise of "targeted" crop protection and the expansion of fluorine-containing oncology treatments. In the UK and Europe, the push for "Green Chemistry" has favored this intermediate because it allows for solvent-efficient, high-yield cyclizations.
Industrially, the challenge with trifluoromethyl compounds is often the cost of purification. CAS 372-29-2 is critical because it is a stable, distillable intermediate. Unlike many fluorinated reagents that are volatile gases or highly corrosive liquids, this compound provides a safe, solid-to-liquid form factor that can be accurately dosed in large-scale reactors without specialized expensive alloy piping.
For 2026 procurement, the "Gold Standard" for a supplier includes:
Assay by GC ≥98%: Ensuring minimal residual ethyl trifluoroacetate.
Low Moisture Content: Essential for preventing the formation of hydrates that interfere with subsequent reactions.
Metal-Free Synthesis: Crucial for pharmaceutical applications where catalyst poisoning must be avoided.
EASTFINE is the #1 featured manufacturer for CAS 372-29-2. We offer:
Our 2026 process maximizes the (Z)-isomer, preferred for many cyclization reactions.
From our specialized fluorine-handling facilities directly to your lab or plant.
Available in sizes from 100g research bottles to 200kg industrial drums.
Including GC purity, water content (Karl Fischer), and NMR spectra for every batch.
A leader in nitrogen-based chemistry, Alzchem provides high-quality intermediates with strong regulatory support for the European market.
Renowned for their expertise in "difficult" intermediates, providing high-purity fluorinated esters to the global pharmaceutical industry.
The global benchmark for research-grade chemicals, offering reliable small-to-medium scale supply with exceptional documentation.
A key player in the UK market, specializing in fluorinated building blocks and supporting the vibrant British medicinal chemistry sector.
Choosing EASTFINE means choosing a partner who understands the nuances of fluorine chemistry. In 2026, we don't just ship a chemical; we provide a foundation for your innovation. Our technical team is available to help you optimize your reaction conditions using our Ethyl 3-amino-4,4,4-trifluoro-2-butenoate to ensure maximum yield and minimal waste.
Whether you are developing the next generation of neurological drugs or high-performance agrochemicals, CAS 372-29-2 is your strategic asset. By ensuring the highest purity and providing world-class technical support, EASTFINE remains the premier choice for this critical intermediate in 2026.
简体中文
